What "adaptogen" means on a label, and what it cannot claim
Ashwagandha, rhodiola and cordyceps have no authorised health claims in Great Britain. What the register says, and the open FSA and COT safety review.
By Stack Almanac
"Adaptogen" is a category invented in 1947 by a Soviet pharmacologist looking for compounds that improved performance under stress. The term travelled from Soviet military research to the wellness aisle by a long route and picked up a lot of unsupported claims on the way. It is still not a category any UK regulator recognises.
That matters more than it sounds. In Great Britain a food or a supplement may only carry a health claim that appears on the GB nutrition and health claims register, in the register's own wording. Ashwagandha, rhodiola and cordyceps have none between them. Not a narrower claim, not a hedged claim: none. The ASA treats the word "adaptogen" itself as an unauthorised claim, because it carries an implied effect.
So this post cannot tell you what they do, and anyone who does tell you is in breach of the code. What it can tell you is what a label should say, what the published safety work says, which of the three has an open UK safety review, and what to run past a pharmacist. That turns out to be the more useful half, and the earlier version of this post had almost none of it.
Ashwagandha (Withania somnifera)
The open safety review
Ashwagandha is the one with an unresolved UK safety question, and that comes before anything else about it. The Food Standards Agency ran a call for evidence on ashwagandha food supplements from 8 July to 2 September 2024, published a summary of the responses on 25 June 2026, and passed the evidence to the Committee on Toxicity for a risk assessment. The COT reviewed a second draft statement at its meeting of 19 May 2026 and a third at its meeting of 8 September 2026. No final statement had been published when we checked.
- The signals the review is looking at, as the work has been described: effects on thyroid hormone levels and reports of thyroid toxicity, hypoglycaemic effects, and possible liver toxicity.
- On the liver question, a 2026 scoping review in Cureus (McIntyre and colleagues) gathered 25 reported cases across 13 publications. Injury usually appeared after weeks of use, the pattern was mostly cholestatic or mixed, and most people recovered after stopping. Among the 25 there was one case of acute liver failure requiring a transplant, and three deaths.
- Case reports are not a rate. 25 cases across the whole published literature tells you a signal exists, not how likely it is. That gap is exactly why a committee was asked rather than a blogger.
- What is already settled: there is no authorised health claim for ashwagandha in Great Britain, and the ASA has upheld complaints against ads claiming it reduces stress and anxiety (Nutriburst Ltd, ruling published 24 July 2024). The advertiser accepted that no ashwagandha health claim had been authorised in the UK.
What to run past a pharmacist
Before it goes anywhere near something you already take, these are the points the person with your list in front of them will want to know about.
- Thyroid. Thyroid hormone effects are among the things under review. If you have a thyroid condition or take thyroid medication, don't add ashwagandha without talking to your prescriber.
- Blood sugar. Hypoglycaemic effects are also under review, which matters if you take anything for diabetes.
- Liver. Stop and get medical advice if you develop jaundice, dark urine, itching, or pain under the right ribs. Those were the presenting signs in the reported cases.
- Pregnancy. Avoid. There is no safety data to support use, which is the whole of the reason.
Reading an ashwagandha label
- What a label should tell you: whether it is a standardised extract and which one (KSM-66 and Sensoril are the two common ones), the amount of extract per capsule, and which part of the plant it came from. If it only says "ashwagandha", you cannot tell what you have bought. Unclear botanical identification and missing amount information are among the reasons the published case reports are hard to assess at all. Our ashwagandha post goes further into the two extracts.
- We are not printing an amount. While a national review of the amounts people take is open, a number from this site would read as a recommendation, and it would be one we cannot stand behind.
Rhodiola (Rhodiola rosea)
Where rhodiola stands
No authorised health claim in Great Britain. The trials people cite are mostly small, mostly in specific groups under fatigue (sleep-deprived students, shift workers, military personnel), and the reviews of them keep landing on the same place: too small and too varied to pool. We went looking for a systematic review we could stand behind, could not confirm the one this post used to cite, and have cut the figure rather than repeat it.
- It turns up combined with caffeine in pre-workout products. There is no authorised claim for the combination, and none for caffeine either: four caffeine claims were vetoed by the European Parliament in July 2016 and never authorised.
Reading a rhodiola label
Look for the standardisation. Rosavins and salidroside are the markers usually quoted, often as 3% rosavins and 1% salidroside. Without those figures two products are not comparable, whatever the milligram number on the front says. No amount from us, for the same reason as above.
What to run past a pharmacist
- Rhodiola has shown weak MAO-A inhibition in laboratory work. That is the basis for the standard warning against combining it with 5-HTP, with a prescribed MAOI, or with SSRIs and SNRIs. Ask your prescriber, not a forum.
- If you have bipolar disorder, raise rhodiola with your prescriber before taking it. Case reports of hypomania exist. Case reports rather than trials, which is a reason to ask rather than a reason to relax.
Cordyceps (Cordyceps sinensis / Cordyceps militaris)
Where cordyceps stands
No authorised health claim in Great Britain. The trials are small, and we could not verify the specific figures this post used to carry, so they have gone. What is left is still worth knowing before you spend money: most products are cultivated Cordyceps militaris rather than wild Cordyceps sinensis, the two are not the same organism, and cheap products can contain very little fungal material at all.
Reading a cordyceps label
Look for the species, whether it is fruiting body or mycelium grown on grain, and whether a marker compound is quantified. A label that says only "cordyceps extract" with a milligram number tells you nothing you can compare with anything.
What to run past a pharmacist
- Cordyceps has been reported to affect platelet aggregation. If you take warfarin, a DOAC, or anything else that affects clotting, ask your prescriber or pharmacist first.
- If you react to mushrooms, treat this as a mushroom.
What is actually comparable
Not the effects, because none of the three has an authorised claim and we are not going to invent a ranking. What you can compare is the paperwork, and the paperwork is genuinely different.
- Standardisation: ashwagandha and rhodiola both have named extracts and marker compounds you can check on a label. Cordyceps mostly does not.
- Open safety reviews: ashwagandha has one in Great Britain right now. Rhodiola and cordyceps do not.
- Interaction questions: rhodiola with serotonergic medicines, ashwagandha with thyroid and diabetes medication, cordyceps with anticoagulants.
- Authorised health claims in Great Britain: none, none and none.
What the word is doing in the marketing
- They are not stimulants, and no UK label may tell you they give you energy. If one does, that is an unauthorised claim and you have just caught it.
- "Balances hormones" means nothing, and no regulator recognises it. Specific hormone effects are exactly what the ashwagandha review is examining, which is the opposite of reassuring.
- They are not a substitute for sleep, daylight, movement or food. Nobody selling them puts that on the front of the tub.
- They are not one thing. Marketing copy groups them because the word groups them, not because the plants have anything in common.
Combining them
The common combinations, and the only honest thing we can say about each.
- Ashwagandha and rhodiola together: different plants, no authorised claim for either, and two sets of interaction questions instead of one. That is the whole of it.
- Ashwagandha and magnesium: magnesium does have authorised wording on the GB register, including "contributes to a reduction of tiredness and fatigue" and "contributes to normal psychological function". Nothing on the register links it to sleep. Putting it next to ashwagandha does not transfer anything in either direction.
- Rhodiola and L-theanine: no authorised claim for either, and "nootropic" is not a recognised category.
- Cordyceps with creatine: creatine is the one supplement in this neighbourhood with an authorised claim. The register wording is "creatine increases physical performance in successive bursts of short-term, high intensity exercise", at a daily intake of 3 g, for adults doing high-intensity exercise. That claim belongs to creatine. It does not extend to whatever it is mixed with.
If you are taking three of these at once you cannot tell which one did anything, and you have tripled the interaction questions rather than the effect. One at a time, or none.
What Stack Almanac does with these
Stack Almanac keeps a dated record of what you take, how much and when, including the extract name where a label gives one. It shows where two products contain the same ingredient and what the combined total is against UK reference values. It carries reference information on known supplement and medicine interactions, with sources, so you can read the same material this page is built on. Check with your pharmacist.
It will also show you when your list has three of these in it at once. That is a count, not a verdict.
The facts
- There is no authorised health claim for ashwagandha, rhodiola or cordyceps on the GB nutrition and health claims register.
- The ASA treats "adaptogen" and "nootropic" as unauthorised claims, and upheld three issues against an ashwagandha ad claiming stress and anxiety benefits (Nutriburst Ltd, 24 July 2024).
- FSA call for evidence on ashwagandha food supplements: 8 July to 2 September 2024. Summary of responses published 25 June 2026. Evidence passed to the Committee on Toxicity.
- The COT reviewed a second draft statement on ashwagandha on 19 May 2026 and a third on 8 September 2026. No final statement published as at 10 October 2026.
- Signals under review: thyroid hormone effects and reports of thyroid toxicity, hypoglycaemic effects, possible liver toxicity.
- A 2026 scoping review in Cureus collected 25 reported cases of ashwagandha-associated liver injury across 13 publications, including one transplant and three deaths.
- Caffeine has no authorised health claim either: four caffeine claims were vetoed by the European Parliament in July 2016.
- Creatine does: "creatine increases physical performance in successive bursts of short-term, high intensity exercise", at 3 g a day for adults doing high-intensity exercise.
Our judgement, kept separate
- The useful thing about these three is not what they do. It is that the label tells you so little about what is in the capsule, and the standardisation is the only part you can check.
- An open national safety review is a reason to wait, not a reason to split the difference with a lower amount.
- If you already take prescribed medication, the interaction questions on this page are worth more to you than any of the removed effect claims were.
What we could not verify
- An earlier version of this post attributed a 2019 anxiety meta-analysis of 5 RCTs to Lopresti, a 2018 systematic review on rhodiola, and a 2017 cordyceps trial in trained cyclists. We could not confirm any of the three to a primary source and have cut them rather than repeat them.
- It also stated cortisol reductions of 20 to 30%, testosterone and sleep effects for ashwagandha, cognitive and depression effects for rhodiola, and VO2 max and lactate threshold effects for cordyceps. All removed: none has authorised wording behind it and we could not verify the underlying figures.
- We could not read the full text of the Cureus scoping review. Its figures come from the published abstract.
- How much the laboratory MAO-A activity of rhodiola matters at the amounts in a capsule is not established in humans, as far as we could find.
Sources
- Great Britain nutrition and health claims (NHC) register, Department of Health and Social Care: gov.uk. The authorised wordings and their conditions of use are the Annex to Regulation (EU) No 432/2012 as it applies in Great Britain: legislation.gov.uk
- Summary of responses to the call for evidence on ashwagandha, Food Standards Agency, published 25 June 2026: gov.uk
- Committee on Toxicity meeting, 8 September 2026 (third draft statement on ashwagandha on the agenda): gov.uk. Second draft statement, 19 May 2026 meeting: gov.uk
- Nutriburst Ltd, ASA ruling A24-1239907, published 24 July 2024: asa.org.uk
- Ashwagandha-associated liver injury: a scoping review, McIntyre and others, Cureus, 2026: pubmed
- Commission Regulation (EU) 2016/1411 (refusing a caffeine and alertness claim): legislation.gov.uk
- Vitamins and minerals: others (magnesium, selenium), NHS: nhs.uk
- CAP Code section 15 (food, food supplements and associated health or nutrition claims) and section 12 (medicines, medical devices, health-related products and beauty products), Committee of Advertising Practice: asa.org.uk
Checked 10 October 2026. Stack Almanac is a supplement tracker and advisor. It does not diagnose, treat or advise on medical conditions, and nothing on this page is medical advice. We don't sell supplements.
Frequently asked questions
Related reading
Mentioned a supplement you want to learn more about? Browse our ingredient reference for UK reference values, forms, timing and pairings.
Check this across your whole routine
Paste the supplements you take. The free check adds up the totals, shows where products overlap, shows general timing information and works out monthly spend, before you create an account.
Audit your supplement routineOccasional field notes
Useful reading, when we have it.
New evidence guides and meaningful product updates. No daily drip, no supplement sales pitch.